ALFA Finder| Revenue growth | 38% YoY growth in Q1FY27. |
|---|---|
| Margins | EBITDA margin improved to 29% from 24% YoY. |
| Order book | 65+ oncology contracts executed; 50+ commercial discussions underway. |
| Demand visibility | Strong demand across countries and new market authorizations. |
| Management confidence | High; citing oncology momentum and expanding market share. |
Growth
Revenue reached ₹7,297 lakhs (+38% YoY); EBITDA at ₹2,125 lakhs (+67% YoY); PAT at ₹1,028 lakhs (+120% YoY).
Outlook
Targeting 100+ overseas contracts and 300+ dossier approvals in 2 years; transitioning to high-margin oncology-led value creation.
Risks
Exposed to global economic performance, international competition, and stringent regulatory requirements for oncology dossiers.
Last quarter's promises, checked
Delivered
- Guided 40% growth for FY26 → delivered 42% (= BEAT)
- Guided EBITDA margin 25-30% → delivered 29% (= BEAT)
- Guided 125 oncology dossiers filed → delivered 178 (= BEAT)
Partly delivered
- Guided 100+ overseas contracts → delivered 65+ (= PARTIAL)
Investor Presentation filed with NSE, NSE: SAKAR. Summary written with AI assistance from the document.
Sakar Healthcare Ltd: key numbers
- Share price
- ₹1,083.70
- Market cap
- ₹2,411 Cr
- Revenue (annual)
- ₹251.7 Cr
- Net profit (annual)
- ₹30.48 Cr
- P/E (TTM)
- 56.2×Sector 43.8×
- Promoter holding
- 51.70%-0.82% QoQ
- FII holding
- 12.34%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Sakar Healthcare Ltd
All →Sakar Healthcare Earnings Call Transcript: Key Takeaways
Sakar Healthcare delivered exceptional growth as its oncology segment scales, with EBITDA doubling and margins expanding significantly due to product-mix shifts. Management is pivoting from a non-oncology focus to high-margin oncology formulations and APIs.
- Call
- Guides 35% growth
Sakar Healthcare Investor Presentation: Key Takeaways
Q2FY27 consolidated revenue Rs87.4 Cr (+52% YoY), EBITDA Rs24.4 Cr (28% margin), PAT Rs11.3 Cr (+149%); pitch centres on oncology integration.
Sakar Healthcare Results Update
Sakar Healthcare reported Q2 FY27 revenue of ₹87.42 Cr and PAT of ₹11.31 Cr, up 149% YoY. EBITDA rose 114% to ₹24.35 Cr on strong oncology approvals and commercial supply commencement.
Sakar Healthcare Q2 FY27 Results: Net Profit ₹11.3 Cr, Up 151.1% YoY
Sakar Healthcare Ltd reported revenue from operations of ₹87.4 Cr (+51.7% YoY) and net profit of ₹11.3 Cr (+151.1% YoY) for Q2 FY27.
- Key figure
- Net profit ₹11.3 Cr · +151.1% YoY
Sakar Healthcare Board Meeting Date
Sakar Healthcare has scheduled a board meeting for October 23, 2026, to approve its unaudited quarterly financial results for the period ended September 2026.
Sakar Healthcare Business Update
Sakar Healthcare says its oncology export model is expanding, with 22 Marketing Authorizations granted and commercial supply starting from its EU GMP site. No monetary value stated.